
BLTE Stock Forecast & Price Target
BLTE Analyst Ratings
Bulls say
Belite Bio is well-positioned with a strong cash position of $798.6M and a market value of $7.77B, supported by discounted cash flow analysis-based asset value and $772.6M in cash and investments. The company's potential approval and successful commercial launch of tinlarebant, its differentiated once daily oral tablet for treating degenerative retinal diseases, and an interim analysis of its Phase 3 PHOENIX trial expected in 2H26, provide potential upside for investors in the long-term, despite risks associated with clinical trials and regulatory approvals.
Bears say
Belite Bio is currently in a critical stage of drug development and regulatory submissions for their lead product candidate, tinlarebant. While they have achieved positive results in their Phase 3 DRAGON trial for patients with STGD1, their success in obtaining regulatory approval from the PMDA in Japan and the FDA in the US is not guaranteed. Additionally, there are significant risks associated with their product's commercial success due to potential competition and market size limitations. Despite having significant cash and investments, Belite Bio remains a high-risk investment due to uncertainties surrounding their drug's clinical efficacy and regulatory approvals.
This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
BLTE Analyst Forecast & Price Prediction
Start investing in BLTE
Order type
Buy in
Order amount
Est. shares
0 shares